Checkpoint Inhibitor denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for checkpoint inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Your Checkpoint Inhibitor — Medical Necessity

UHC's medical-necessity denials for checkpoint inhibitors typically arise because the submitted clinical information did not clearly demonstrate that the patient meets UHC's coverage criteria for the specific drug and indication. Common gaps include: insufficient biomarker documentation; missing staging or histology confirmation; inadequate documentation of prior treatment history; or a clinical presentation that UHC's reviewers determined did not meet the threshold defined in its coverage policy.

This denial is not final. Medical-necessity determinations are among the most frequently reversed denial types in oncology, particularly when a well-documented appeal is submitted with a complete clinical record.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial notice. Request expedited review (72-hour decision) if continued treatment is time-sensitive.
• Peer-to-peer review: Before or alongside the formal appeal, the prescribing oncologist should request a peer-to-peer call with UHC's medical reviewer — this alone resolves many medical-necessity denials.
• ACA §2719 external review: If the internal appeal is denied, request independent external review within the ~4-month statutory window. The external reviewer applies "generally accepted standards of medical practice."
• ERISA §503 (employer plans): You are entitled to the full clinical criteria UHC applied, including the specific coverage policy and any clinical guidelines referenced.

## Documentation to Gather

1. Diagnosis and staging: Complete pathology report, staging workup, and any relevant imaging establishing the diagnosis and extent of disease. 2. Biomarker and genomic testing: Results for all relevant markers (e.g., PD-L1 expression level, MSI/TMB status, tumor genomic profile) — these are typically gating criteria in UHC's coverage policy for checkpoint inhibitors. 3. Prior treatment history: Chart documentation of each prior line of therapy with start/stop dates, doses, and response or toxicity outcome — demonstrating where the patient is in the treatment sequence. 4. Performance status and clinical severity: ECOG or Karnofsky performance status assessment, recent labs, and any organ-function documentation relevant to treatment eligibility. 5. Prescriber medical-necessity letter: A detailed, criteria-directed letter from the oncologist mapping each UHC coverage requirement to a specific chart fact.

## Criteria-Mapping Structure

Obtain UHC's current coverage policy for the specific checkpoint inhibitor and list every criterion it requires. Then, for each criterion, cite the exact chart document and finding that satisfies it — lab report with date, pathology finding, imaging result, performance status note. This structured format makes it impossible for a reviewer to claim the information was not provided, and it directly addresses the basis of the denial.